Get started

GLAXO

Glaxosmithkline looking good. GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company. Their product offering include vaccines, speciality medicines & general medicines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. GlaxoSmithKline Pharmaceuticals CMP is 1390.95. Negative aspects of the company are high valuation (P.E = 38.6), declining annual net profit & MFs are decreasing stake. Positive aspects of the company are improving cash from operations, no debt & zero promoter pledge. Entry after closing above 1402. Targets in the stock will be 1435 & 1461. Long term target in the stock will be 1489. Stop loss in the stock should be maintained at closing below 1288.
NSE:GLAXOLong
by Happy_Candles_Investment
GSK Death Cross my be hugely bullish after all !GlaxoSmithKlein (GSK) just formed a Death Cross on the 1D time-frame, which is when the 1D MA50 (blue trend-line) crosses below the 1D MA200 (orange trend-line). This is technically a bearish pattern but last time it formed (March 24 2020) was exactly on the bottom of the COVID crash and the price recovered rapidly. That was of course in the aftermath of the massive economic package in an attempt to support the economy from the lockdown but even now there is upside potential and some levels to consider on the short-term. As you see, since April 11, the stock has been trading within a perfect Channel Down. This indicates a systematic downtrend. As long as the 1D MA50 holds, such rises are sell opportunities towards a Lower Low, in which case its on the 0.236 now. Since we are trading so close to the 1D MA50, a tight sell now with the SL located at the top of the Channel Down, has an excellent Risk/ Reward ratio. Similarly, if the price breaks above the top of the Channel Down, the R/R is favorable in going on a tight buy targeting the upper Fibs and ultimately the 47.00 Resistance. Notice how the 1D RSI bounced off near the 30.00 oversold level, which has initiated massive rebounds another 4 times within the long-term Channel Up. -------------------------------------------------------------------------------------------------------- ** Please support this idea with your likes and comments, it is the best way to keep it relevant and support me. ** --------------------------------------------------------------------------------------------------------
NYSE:GSK
by TradingShot
1
NIFTY - Test Of 8200 / 8000 Inevitable - 11/4/2016Happy New Year to all. New year has arrived with new opportunities. It is always good to start a new year with profitable note. Our short NIFTY and other selected stocks positions ( via puts of courses ) is well in green and now it looks like the test of solid support levels near 8200 / 8000 is inevitable in coming sessions. Many of the trades we have outlined here have performed the way sound technical analysis defines the chart geometry. Trading theme is, soggy IT sector, topped out auto and pharma sector, so-so oil sector and healthy but lack of momentum in FMCG sector. Here are some of the trades you can review based on such theme, ( Pls Check the Links ) Dr Reddy Cipla Glaxo Lupin Infosys TCS Wipro ONGC Dabur Grasim We have warned about sucker rallies in equities and have advised to be patient with a game plan. Armature investors ask wrong questions about what's going to happen and they tend to waste energy in trying to find when a particular security is going to reach 'where they believe it is heading towards'. Nobody can predict the exact timing and where the things are going to be. Only thing which matters is that what you are going to do when the stock reaches to the point you are interested in ! e.g. people ask, when XYZ stock will reach 100? Instead they should be thinking about what they will do when it reaches 100 or 50 or whatever level is defined as good support or resistance. Let's enjoy the relaxed last weekend of Diwali holidays and get ready for the next week to trade Forex, Commodities and Equities. We are ready with a game plan for the new year, are you?!
NSE:NIFTY
by BombayBulls
Glaxo SmithKline (GSK) Pharma – What's Next? – 9/20/2016Preaching for patience by setting the examples ;) Roughly 6 months ago we published this piece on technical analysis of Glaxo SmithKline Pharmaceutical Stock. ( bombaybulls.com )It was mentioned clearly in that post that buying the stock near 3600 ( it was trading near that price in March, 2016 ) and hoping for it to reach 4000 might be a gamble ! Six months forward and we are back to 2800. At that time we were relying on 3000 - 3200 range and few short term trades did materialize but nothing substantial. Here comes a crucial part about technical analysis which helps you determine whether to trust on a support / resistance level and up to what extent ! There is no easy answer for that because it requires both expertise and experience. So now it looks like the one and half year old range has finally broken to the downside and it will more likely to test the next lower range support area near 2400 - 2600 in coming sessions. Again we are in wait and be patient mode until good opportunity arises to grab it near the above mentioned support area. Here one thing we would like to mention that in general equity market is looking rich ( but who cares about valuation these days ! ;) ) and as a good student of history we would like to be very cautious. Because things happen when they are least expected in stock market. Currently everybody is in buy the dip mode but if not tomorrow then some day after tomorrow it will stop working for sure. Most pharmaceutical stocks are beyond stratosphere these days and the day of reckoning will of course come. Thus, even at 2400 - 2600, we will look for trading opportunities rather than long term holding opportunities. Of course, you never know for sure but grab with hand over fist moment doesn't materialize until there is full blown mayhem and we get the stock at 1/3 of today's price !
NSE:GLAXOLong
by BombayBulls